γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
Rebecca Rawlinson(Granta Design (United Kingdom)), Andrew J. Massey(Granta Design (United Kingdom))
Cited by 33
Related Papers
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
|BMC Cancer|2014|110
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
|Molecular Cancer|2014|53
Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC
|PLoS ONE|2015|46
Identification of novel,<i>in vivo</i>active Chk1 inhibitors utilizing structure guided drug design
|Oncotarget|2015|44
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
|Molecular Oncology|2015|24